- Home
- MNTK vs VNDA Comparison
MNTK vs VNDA Comparison
Compare MNTK & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MNTK | VNDA |
|---|---|---|
| Founded | 1980 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 267.6M | 301.1M |
| IPO Year | 2020 | 2005 |
Fundamental Metrics
Financial Performance| Metric | MNTK | VNDA |
|---|---|---|
| Price | $2.40 | $3.71 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $1.70 | ★ $11.50 |
| AVG Volume (30 Days) | 594.2K | ★ 1.1M |
| Earning Date | 11-09-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $176,382,000.00 | ★ $216,105,000.00 |
| Revenue This Year | $20.57 | $12.05 |
| Revenue Next Year | $16.34 | $30.61 |
| P/E Ratio | $146.00 | ★ N/A |
| Revenue Growth | 0.37 | ★ 8.72 |
| 52 Week Low | $1.07 | $3.70 |
| 52 Week High | $3.28 | $9.91 |
Technical Indicators
Market Signals| Indicator | MNTK | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 53.46 | 32.87 |
| Support Level | $1.56 | N/A |
| Resistance Level | $2.73 | $5.49 |
| Average True Range (ATR) | 0.14 | 0.25 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 90.48 | 21.28 |
Price Performance
Historical ComparisonAbout MNTK Montauk Renewables Inc.
Montauk Renewables Inc is a renewable energy company. It specializes in the recovery and processing of biogas from landfills and other non-fossil fuel sources for beneficial use as a replacement for fossil fuels. The firm develops, owns, and operates RNG projects that supply renewable fuel into the transportation and electrical power sectors. Montauk operates in two segments namely Renewable Natural Gas and Renewable Electricity Generation. It generates a majority of its revenue from the Renewable Natural Gas segment.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.